Measurement of glomerular filtration rate in ICU patients using 99mTc-DTPA and inulin  by Wharton, William W. et al.
Kidney International, Vol. 42 (1992), pp. 174—178
Measurement of glomerular filtration rate in ICU patients using
99mrfcDTpA and inulin
WILLIAM W. WHARTON III, JILL L. SONDEEN, MICHAEL MCBILES, STEPHEN E. GRADWOHL,
CHARLES E. WADE, DAVID P. CIcERI, HEINZ G. LEHMANN, RICHARD E. STOTLER,
THOMAS R. HENDERSON, W. ROSCOE WHITAKER, and JILL S. LINDBERG
Department of Medicine, Nuclear Medicine Service, Department of Radiology, and Pharmacy Service, Letterman Army Medical Center, and
the Division of Military Trauma Research, Letterman Army Institute of Research, Presidio of San Francisco, San Francisco, California; Life
Sciences Division, NASA Ames Research Center, Moffett Field, California; and Department of Internal Medicine, Section on Nephrology,
Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana, USA
Measurements of glomerular filtration rate in ICU patients using
99mTcDTpA and inulin. Improved and reliable methods for assessing
glomerular filtration rate (GFR) in intensive care patients are needed in
light of known deficiencies using creatinine clearance. We compared
simultaneous two-hour clearances of inulin (C1), creatinine (C.), and
s9mTcdiethylenetriaminepentaacetic acid (CDTPA) in 18 medical or
surgical intensive care patients (range, 49 to 92 years old) with blood
urea nitrogen (BUN) levels >17.9 mmol/liter (0.5 mg/mI), serum creat-
mine levels >150 mol/liter (0.02 mg/mI), or estimated Cockcroft
clearance <60 mI/mm. Patients had severe renal dysfunction with
average GFR of 35 mi/mm (range, 2 to 69 mI/mm). CDTPA and C.
correlated significantly with C1,,, although CDTI?A tended to provide a
closer approximation. Cockcroft clearance (32 4 mI/mm) was grossly
similar to CDTPA and C1,, and correlated significantly, especially when
weight was calculated using actual as opposed to ideal body weight. In
a subset of 13 patients with C1,, <30 mI/mm, only CDTPA was signifi-
cantly correlated with C1,,. In patients in the intensive care unit, CDTPA
providesa rapid, accurate, and inexpensive clinical assessment of GFR,
even at very low GFRs.
The measurement of serum creatinine and creatinine clear-
ance remains the standard technique for assessing renal func-
tion despite its poor correlation with actual GFR as measured
by inulin clearance [1—5]. Over the past decade, rapid, accurate
techniques have been developed using radiopharmaceuticals to
measure true GFR in patients with varying levels of renal
dysfunction [1—101. These agents are well studied in patients
with stable renal disease but have not to our knowledge been
tested in the critical care setting where alterations in muscle
mass, metabolism, body water and renal function may cause
errors in estimating renal function from serum creatinine, and
renal dysfunction alters the accuracy of creatinine clearance
due to secretion of creatinine [41. In this study, we assessed the
use of 99mTcDTPA urinary clearance in the clinical measure-
ment of GFR in critically ill patients with both severe renal
dysfunction and acute systemic disease.
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Methods
Patient population
Eighteen medical and surgical patients, aged 49 to 92 years,
admitted to our medical-surgical intensive care unit were re-
cruited on the basis of chart review and results of admission
laboratory studies. Six were surgical patients: Two had thoracic
and four had abdominal procedures. The remaining 12 patients
were medical patients with diagnoses ranging from hyperten-
sive crisis to end-stage myeloma with congestive heart failure,
pneumonia, and sepsis (Table 1). All had acute renal failure;
some had acute renal failure superimposed on chronic renal
failure. Patients were considered for study if they met one or
more of the following criteria: BUN >17.9 mmol/liter (0.5
mg/ml), serum creatinine >150 mmollliter (0.02 mg/mI), or
estimated Cockcroft clearance 60 ml/min [11]. Patients cur-
rently undergoing dialysis were excluded due to wide fluctua-
tions in serum BUN and creatinine levels. Patients who had
received dextran or hetastarch were not studied since these
agents interfere with the inulin assay [121. Patients with urine
flow <20 mI/hr were excluded because of the necessity to
obtain an adequate urine collection.
Study design
After informed consent was obtained, the inpatient records
were reviewed to collect data on admission and preadmission
laboratory studies, reasons for critical care monitoring, medical
history, current medications, and nutritional support. Inulin
doses needed to achieve constant serum levels were calculated
using serum creatinine level and ideal body weight estimated
from Metropolitan Life tables. Inulin was prepared in the
hospital pharmacy. The mTcDTPA was prepared by the
Nuclear Medicine Service on the day of study using commer-
cially available kits (Medi + Physics, Paramus, New Jersey,
USA). After collection of background serum and urine samples
using existing vascular and Foley catheters, a 200-pCi dose of
99mTCDTPA was administered by intravenous bolus. This was
followed by a priming dose of inulin and subsequent three-hour
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Table 1. Patient information
No. Diagnosis Sex Age
'cr
mg/dl
BUN C1 CDTPA C2 hr Cr
mi/mm
I Lymphoma F 63 1.9 41 21 23 34
2 Laparotomy, abscess M 63 1.9 24 69 68 55
3 Laparotomy, perforated M 61 1.3 42 61 68 69
ulcer
4 Post myocardial M 67 5.8 88 23 21 18
infarction
5 Lymphoma F 63 4.0 37 7 8 13
6 Pneumonia M 74 1.2 28 25 30 36
7 Pulmonary edema F 70 1.8 58 42 58 59
8 Bilateral renal artery F 67 2.2 29 13 20 28
bypass
9 Unstable angina, M 73 2.0 21 25 21 25
hypertensive crisis
10 Post myocardial M 65 2.5 20 19 44 52
infarction
11 Pulmonary edema F 92 0.7 16 31 62 55
12 Aortic valve F 77 3.2 72 2 2 4
replacement, coronary
artery bypass
13 Coronary artery bypass, F 49 1.6 36 22 32 54
concomitant jaundice
14 Pulmonary edema M 80 3.7 52 12 13 28
15 Exacerbation of chronic M 75 3.8 77 25 19 24
obstructive pulmonary
disease
16 Small bowel resection F 84 2.4 81 20 17 22
17 Multiple myeloma, M 61 2.2 41 36 23 36
congestive heart
failure, pneumonia
18 Pulmonary edema M 80 3.4 65 17 13 14
Cr and BUN values are study entry values.
inulin infusion. Serum and urine samples were then collected at
60-, 120-, and 180-minute intervals. At each collection period,
emptying of the bladder was maximized by bladder massage,
urine in the Foley system was mixed, and total urine volume
was recorded. A 10 ml aliquot was then drained off and the
remaining urine discarded. At the same time, a 10 ml sample of
serum was collected using existing vascular access.
Sample analysis
Activity of 99mTc.DTPA was determined immediately after
each experiment in the radioimmunoassay laboratory using a
standard 20-well gamma counter. There was no correction for
protein binding. Two-hour urinary clearances of creatinine,
inulin, and 99mTcDTPA were calculated using the standard
method [(U x V)/P, where U is the urinary concentration of the
substance, V is the urine flow rate in mI/mm, and P is the
plasma concentration of the substance]. Inulin was assayed via
spectrophotometry using the Anthrone method [12]. Creatinine
was measured by a modified Jaffe method [13], using a Cobas
autoanalyzer. The two-hour clearances were calculated as the
arithmetic average of urinary excretions (U x V) of the 60 to
120-minute and 120- and 180-minute collection periods divided
by the average of the three plasma measurements. A 24-hour
urine was ordered on each patient. Cockcroft clearance was
estimated, using both actual and ideal body weight, according
to the formula:
CCOckcOft mI/mm =
(140 — age year) (weight kg) (0.85 for females)
(72) (serum creatinine mgIlOO ml)
Statistical analysis
With the assumption of a zero intercept, the data were fitted
to a regression line. The slopes were then used to determine
whether or not the clearance of 99mTcDTPA and creatinine
were equivalent to inulin clearance (that is, slope = 1) by the
Student's i-test. In addition, we also compared whether the
slopes of the two lines (CDTPA-CIfl and CrCi lines) were
equivalent by a t-test. We also determined whether the DTPA
was on the linear portion of its plasma decay curve following
the bolus injection of DTPA, and whether the results from
one-hour collection periods were reproducible. A significance
level of 0.05 was used for all statistical tests. Data given in the
test are mean SE
Results
Patient demographics and intensive care unit diagnosis are
indicated in Table 1. Plasma creatinine, urea nitrogen, and
Cockcroft formula clearance values are those obtained, at entry
into the study. The table also includes results of obtained inulin,
DTPA, two-hour, and 24-hour creatinine clearances.
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Urinary clearance of 99mTcDTPA was significantly corre-
lated with inulin clearance (r = 0.85, P < 0.001, CDTPA = 1.12
x C) (Fig. 1). Two-hour creatinine clearance slightly overes-
timated inulin clearance but was still correlated despite more
variation in individual measurements (Ce. = 1.18 x C1,,, r =
0.64, P < 0.005) (Fig. 1). Interestingly, estimated Cockcroft
clearance was significantly but not strongly correlated to inulin
clearance, especially when calculated using actual (CCockcr,,ft
1.06 x C1,, r = 0.64, P < 0.005) as opposed to ideal body weight
(CCoCkcrOft = 1.09 x C1,, r = 0.59, P < 0.01) (Fig. 2). In the 13
patients with inulin clearance less than 30 ml/min, CDTPA was
strongly correlated with C1,, (CDTPA + 1.106 x C1,,, r= 0.65, P
<0.02) while C. and CCockcroft did not correlate (Fig. 3).
Because two-hour urinary clearance measurements are un-
usual in a clinical setting, we wanted to ascertain whether
one-hour urine collection periods were reproducible. There
were inaccuracies in the urine collections: 5 of the 18 patients
had 50 to 60% coefficient of variability (CV) of urine volume
rather than the expected 10 to 20%. These same patients had
large differences in GFR between the two measurement peri-
ods, but these differences were directly related to the differ-
ences in urine volume (that is, there were no corresponding
changes in endogenous creatinine levels which would have
occurred had the GFR actually changed between measure-
ments). To minimize the effect of the inaccurate urine collec-
tion, we pooled the volumes over the two hours, assuming that
any urine which was missed in one specimen would be collected
in the other. However, if each one-hour period is analyzed
separately, the same relative findings result. Only 50% of the
24-hour urines ordered were collected. All of those obtained
were inadequate specimens based on creatinine index, total
volume, and known collection errors.
We were also concerned about the stability of the plasma
levels of both the infused inulin and the endogenous creatinine
as well as whether the DTPA was on the linear portion of its
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Fig. 1. Clearances of DTPA (CDTPA = 1.12 >< C1,,, r = 0.85, P <0.001)
and creatinine (C 1.18 x C1,,, r = 0.63, P < 0.005) were significantly
correlated with the clearance of inulin. The slopes of the regression
lines for CDTPA (— —) and for Cc. (- -) were not significantly different
from the line of identity ( ).
Cl
Fig. 2. Cockcroft clearance, calculated using either actual bod)
weight [(——), Cc,,Ck,.,,,f, = 1.06 x C,,,, r 0.64, P <0.0051 or idea
body weight [(- -), = 1.09 x C,,,. r 0.59, P < 0.011 estimatec
from Metropolitan Life tables based on height and age, was sign(fi
cantly correlated with clearance of inulin. The slopes of the regressior.
lines were not significantly different from the line of identity ( ).
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Fig. 3. The clearance of DTPA was significantly correlated with the
clearance of inulin in the subset of patients having C,,, < 30 mI/mm
((———-—) = 1.106 x C,,,, r = 0.65, P < 0.021. For this
subset of patients, neither creatinine clearance (r = 0.45, NS) nor
Cockcroft clearance (based on actual body weight; r = 0.43, NS) were
significantly correlated with inulin clearance [line of identity: ( )].
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plasma decay curve following the bolus injection of DTPA.
Following an initial one-hour infusion period, the plasma levels
of inulin were stable when measured at one hour intervals. The
levels were 0.27 0.08, 0.28 0.09, and 0.29 0.08 mg/mi at
60, 120 and 180 minutes, respectively. The CV was 8%. The
plasma creatinine concentration for 60, 120, and 180 minutes
was 2.41 0.79, 2.45 0.84, and 2.45 0.87 mg/dl, respec-
tively, and had a CV of 2%. The average counts per minute
(cpm) for the plasma DTPA decreased as expected following
the bolus injection: the counts were 6668 1578, 5608 1428,
and 5041 1337 cpm at the 60, 120, and 180 minute samples,
respectively, with CV of 13%. We calculated DTPA clearance
both logarithmically and arithmetically and obtained similar
results. Thus, we validated the use of the arithmetic average of
the three plasma levels over the period of collection for sim-
plicity of calculation.
Discussion
Creatinine clearance remains the standard technique for
assessing renal function, despite its inadequacies [5, 14]. The
continued popularity of creatinine measurement is likely the
result of historical familiarity as well as the widespread avail-
ability of inexpensive creatinine assays [14]. In 1985, Shemesh
et a! [4] advocated the use of radiopharmaceuticats in the
investigational and clinical determination of GFR, based on
ample data that creatinine clearance is too variable to provide
useful clinical information in patients with severe renal dysfunc-
tion. Subsequent investigations, including a recent paper by
Perrone et al. [15], have clearly shown that GFR can be rapidly
and accurately measured with radiopharmaceuticals in both
research and clinical settings [5, 4, 151. Based on these data,
and the observation that many of the conditions that confound
the clinical assessment of renal dysfunction are found in the
intensive care unit, we believe that this setting would be ideal
for the use of a two-hour 99mTcDTPA clearance in the clinical
assessment of GFR. Although many agents have been proven to
be accurate in assessing GFR, we chose 99mTcDTpA because
of its relatively low cost and widespread use in clinical nuclear
medicine departments. In comparison with other widely tested
markers such as iothalamate and EDTA, 99mTcDTPA is also
readily available and easily prepared using commercially avail-
able kits. There are often problems with spillage, loss of
samples, and inadequate collection associated with the tradi-
tional 24-hour urine creatinine clearance. In addition, the ICU
patient with acute renal failure may have rapidly changing renal
function, which often makes a 24-hour test difficult to interpret
and a two-hour test preferable in this setting.
The results of this study demonstrate the utility of using
99mTCDTpA to determine GFR in the critical care setting.
Surprisingly, both estimated Cockcroft clearance and two-hour
creatinine clearance were correlated with C1 at GFR in the
range of 30 to 100 mi/mm. When, however, GFR fell below 30
mi/mm, a level that may affect drug dosage and decisions
regarding renal replacement therapy, CCR and CCockcroftwere
not correlated with C1. However, CDTPA was statistically
correlated with C, at all levels of renal function. The correla-
tion of 99"Tc-DTPA clearance with inulin clearance is moder-
ately good with an r value of 0.85. This correlation is not as high
as that observed in the studies conducted by Sheniesh et at [4]
and Perrone et al [15] who utilized a much greater range of GFR
(0 to 140 mI/mm and 0 to 125 mI/mm, respectively), whereas our
study utilized a much smaller range of GFR. When the range is
increased although variability remains the same, the correlation
will be higher for purely mathematical reasons and not because
the relation is truer. In addition, the lower correlation in our
study may be explained by the fact that the patients in the above
mentioned studies were "stable" without medical illnesses or
received a water load medication that would alter renal function
and maximize urine flow [4, 15]. The goal of our study was
simply to evaluate the use of DTPA in the "unstable" but
"typical" ICU patient with tow GFR, and with medical ill-
nesses and medications that definitely altered renal function.
For these reasons and the inability to water load these unstable
patients, GFR measurement is difficult. Therefore, a correlation
of 0.85 between inulin and DTPA is a good one in the compli-
cated patient evaluated in our study.
The benefits of low expense, rapid turnover time, ease of
sample collection, and documented accuracy at all levels of
GFR make DTPA a viable alternative to the traditional creati-
nine assay. We conclude the mTcDTPA urinary clearance
provides a rapid, accurate, and clinically proven method of
determining GFR that can be very useful in the critical care
setting.
Perhaps of greater significance in our study was the gross
overestimation of GFR when assessed by serum creatinine.
Patients in the normal or near-normal range of serum creatinine
had a significantly depressed GFR as assessed by inulin clear-
ance. Conceivably, the high incidence of acute renal failure in
the critical care setting, estimated to be between 15 and 30
percent [16], could be caused by failure of clinicians to recog-
nize the degree of renal dysfunction in this setting, possibly
leading to the prescription of drugs in improper dosages and the
exposure of patients to procedures that may cause nephrotox-
icity.
Furthermore, decisions concerning the need for dialytic
therapy of acute renal failure are generally based on many
factors including levels of creatinine and BUN. Possibly with
the overestimation of GFR that occurs when assessed by serum
creatinine, patients should have dialysis initiated at lower
serum levels of creatinine and BUN. While we do not advocate
the use of mTcDTPA clearance in all critical care patients,
certain high-risk patients such as the insulin-dependent diabetic
and the elderly probably do merit a more sophisticated assess-
ment of GFR than that provided by serum creatinine.
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